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Introduction. Subclinical hypothyroidism (SCH) is deﬁned as a serum thyroid-stimulating hormone (TSH) level above the upper
limit of normal despite normal levels of serum free thyroxine. There is growing evidence that SCH is associated with increased
cardiovascular risk. We tried to investigate prevalence of SCH in acute myocardial infarction patients. Methods and Results.W e
evaluate free T3, free T4, and TSH levels of 604 patients (age 58.4) retrospectively, who have been admitted to the coronary
intensive care unit between years 2004–2009 with the diagnosis of ST elevation (STEMI) or non-ST elevation acute myocardial
infarction (NSTEMI). Mild subclinical hypothyroidism (TSH 4.5 to 9.9mU/l) was present in 54 (8.94%) participants and severe
subclinical hypothyroidism (TSH 10.0 to 19.9mU/l) in 11 (1.82%). So 65 patients (10.76%) had TSH levels between 4.5 and 20.
Conclusions. In conclusion,65 patients (10.76%) had TSH levels between 4.5 and 20 in our study, and it is a considerable amount.
Large-scale studies are needed to clarify the eﬀects of SCH on myocardial infarction both on etiologic and prognostic grounds.
1.Introduction
Subclinicalhypothyroidism (SCH) is deﬁned as a serum thy-
roid-stimulating hormone (TSH)level above the upper limit
of normal despite normal levels of serum free thyroxine [1].
Subclinical hypothyroidism or mild thyroid failure is a
common problem, with a prevalence of 3% to 8% in the
population without known thyroid disease [2, 3]. The preva-
lenceincreases with ageand ishigher in women[2].Afterthe
sixth decade of life, the prevalence in men approaches that
of women, with a combined prevalence of 10%. Antithyroid
antibodies can be detected in 80% of patients with SCH, and
80% of patients with SCH have a serum TSH of less than
10mIU/L.
There is growing evidence that SCH is associated with
lipid abnormalities, increasing cardiovascular risk, particu-
l a r l yi no l d e rw o m e n[ 4, 5]. Clinical hypothyroidism is asso-
ciated with premature atherosclerosis and increased preva-
lence of coronary disease. This is at least partly due to
the lipidabnormalities often foundin hypothyroidism [6,7].
Possible mechanisms behind the link between hypothyroid-
ism and atherosclerosis, other than dyslipidemia, include the
eﬀects of thyroid hormones on coagulation, vasodilation,
parasympatheticfunction,andhomocysteinemetabolism[4,
8].
A study, which examined the relation between cardio-
vascular disease and TSH levels in euthyroid patients, found
signiﬁcantly higher TSH in patients with coronary events
compared to controls matched for age, gender, and body
mass index [9]. The cross-sectional Rotterdam study showed
an association of SCH with myocardial infarction and aortic
calciﬁcation [10].
Several observational studies comparing the outcome of
SCH individuals with euthyroid subjects have shown diver-
gent results, and it has been debated for some time whether
SCH is independently associated with ischemic heart dis-
ease (IHD) [11, 12]. If the latter were true, this would be2 ISRN Endocrinology
an important public health issue for the aging population,
in which SCH is most prevalent [2].
As ﬁndings of several studies support the inﬂuence of
SCH on ischeamic heart disease, we tried to investigate
prevalence of SCH in acute myocardial infarction patients.
2.Methods
We evaluate free T3, free T4, and TSH levels of 604 patients
(age 58.4) retrospectively, who have been admitted to the
coronary intensive care unit between years 2004–2009 with
the diagnosis of ST elevation (STEMI) or non-ST elevation
acute myocardial infarction (NSTEMI). Patients were classi-
ﬁ e di n t o2g r o u p sb a s e do nt h e i rt h y r o i df u n c t i o nt e s t s[ 13],
subclinical hypothyroidism: TSH > 4.50 and <20.0mU/L
with a normal FT4 (n = 65) and patients with normal TSH
and FT4 levels.On the basis of the deﬁnitions used by the US
Preventive Services Task Force [14] and on expert consensus
[15], subclinical hypothyroidism was subclassiﬁed according
to the following TSH levels, 4.5 to 9.9mU/L (n = 54)
and ≥10.0mU/L (marked elevation, n = 11), because of
possible greater risks above this cutoﬀ. We collected self-
reported alcohol and smoking status. All physical examina-
tion ﬁndings including blood pressure, heart rate, and body
mass index were noted. Hypertension was deﬁned as self-
report and the use of antihypertensive medications or as
a blood pressure ≥140/90mmHg. Diabetes was deﬁned as
af a s t i n gg l u c o s e≥120mg/dL or the use of hypoglycemic
medication.Atrialﬁbrillation atbaseline wasself-reported or
determined on electrocardiogram or with a Holter monitor.
For prevalent HF at baseline, self-reports were conﬁrmed by
physical examination and echocardiography.
3.Results
The mean age was 58.4 years. More than half of the patients
(55.6%) were males (Table 1). Mild subclinical hypothy-
roidism (TSH 4.5 to 9.9mU/L) was present in 54 (8.94%)
participants and severe subclinical hypothyroidism (TSH
10.0 to 19.9mU/L) in 11 (1.82%). So 65 patients (10.76%)
had TSH levels between 4.5 and 20. Subclinical hypothy-
roidism was more common among men in our study pop-
ulation. However, severe SCH was more prominent among
women. Age, history of DM, history of hypertension, previ-
ous MI, presence of AF, increased diastolic blood pressure,
increased triglyceride levels, inhospital deaths, and history
of heart failure all were statistically more prominent among
SCH patients with TSH levels between 10 and 19.9 (Table 1).
Inhospital deaths, history of heart failure, HT, and DM were
signiﬁcantly higher in overall SCH patients than patients
with normal TSH levels.
4.Discussion
This study is a descriptive study aiming to evaluate SCH
prevalence among patients with acute MI and, demo-
graphic diﬀerences between patients with and without SCH.
This study does not provide any insight into the potential
mechanisms ofanyadverseeﬀectsofSCHoncoronaryartery
disease.
Inourstudy,inhospitalmortalitywassigniﬁcantlyhigher
among patients with SCH. The cross-sectional Rotterdam
study showed an association of SCH with myocardial infarc-
tion and aortic calciﬁcation [10]. In contrast, the Wickham
study [16] showed no increased cardiac mortality in a 20-
yearfollowup.Amorerecentobservationalstudyalsodidnot
show any association between unrecognized SCH and
cardiovascular events or mortality [13]. However, several
more recent meta-analyses of observational studies found
an association between SCH and coronary artery disease
[17–19]. The risk is lower when higher quality studies are
pooled [18]. A recent analysis of 7 cohort studies concluded
that the relative risk of all-cause mortality was increased
compared with euthyroid controls, particularly in patients
with comorbid conditions [20]. Another meta-analysis of
15 studies showed an increased prevalence and incidence of
cardiovascular mortality only in a relatively younger pop-
ulation [21]. Taken together, the ﬁndings of these 6 recent
meta-analyses suggest that a cardiovascular risk exists for
persons younger than age of 70 years with no eﬀect for
t h o s ea g e d7 0t o8 0y e a r sa n dap o s s i b l yp r o t e c t i v ee ﬀect
for those older than 80 years [22]. Thus, the cardiovascular
risk issue remains controversial, and large-scale, multicenter,
randomized, placebo-controlled studies are needed to assess
the eﬃcacy of levothyroxine therapy in risk reduction.
Because of its high prevalence in the population and
its adverse eﬀects on lipid proﬁle and hence increased car-
diovascular risk, hypothyroidism is the principal functional
disorder. Lipid anomalies associated with hypothyroidism
are at least partially responsible for the increase in coronary
heart disease. In our study, the lipid proﬁles of patients
with and without SCH were similar. Only triglyceride levels
were signiﬁcantly higher in patients with TSH levelsbetween
10–19.9 than euthyroid patients. Lipid abnormalities vary
greatly between individuals, and the relationship between
SCH, dyslipidemia, and cardiovascular risk is still the subject
of debate [1]. The Colorado Health Fair study showed that
the mean total cholesterol level was 216mg/dL for euthyroid
patients and 224mg/dL for patients with SCH [23]. Several
randomized studies have shown reduction of low-density
lipoprotein cholesterol by levothyroxine therapy. However,
most of the studies showing beneﬁt are not categorized for
serum TSH levels of 5.0 to 10.0mIU/L. A meta-analysis
of 13 studies concluded that the lipid proﬁle improved
with therapy [24]. In a 2004 review, data were considered
insuﬃcienttoshowbeneﬁtsoflevothyroxinetherapyonlipid
levels [15].
Thyroid hormones modulate enzyme activity, receptor
expression, and lipid breakdown and clearance, thereby
contributing to the expression of the lipid phenotype. The
spectrum of thyroid dysfunction is associated with diﬀerent
levelsofcardiovascularrisk,asdemonstratedbyindependent
changes in the severity of risk factors that have been linked
to cardiovascular morbidity in many studies. The increase in
cardiovascular risk, most clearly associated with hyper- and
hypothyroidism, isduenotonlytoalterationsinlipidproﬁle,
but also to hemodynamic changes, endothelial dysfunction,ISRN Endocrinology 3
Table 1: Baseline characteristics of the patients according to thyroid status. (Values are mean ± SD percentages. ∗P<0.05 compared with
euthyroid category.)
Total
(n = 604)
All subclinical
hypothyroids
(n = 65)
Subclinical hypothroid
(TSH= 4.5–9.9),
(n = 54)
Subclinical hypothyroid
(TSH= 10–19.9),
(n = 11)
Age (years) 58.4 59.9 59.4 64.2∗
Sex (male/female) 336/268 41/24 37/17 4/7
Active smoker 107 (17.7%) 8 (12.3%) 7 (12.9%) 1 (9%)
Alcohol 109 (18%) 7 (10.76%) 6 (11.1%) 1 (9%)
Diabetes mellitus 103 (17%) 17 (26.15%)∗ 13 (24%) 4 (36.3%)∗
Hypertension 296 (49%) 37 (56.9%)∗ 29 (53.7%) 8 (72.7%)∗
Previous MI 62 (10.2%) 11 (16.9%) 7 (12.9%) 4 (36.3%)∗
Atrial ﬁbrillation 71 (11.7) 10 (15.38%) 7 (12.9%) 3 (27.2%)∗
BMI (KG/M2) 28.2 29.4 29.3 29.7
Systolic BP 138.4 141.5 141.3 142.5
Diastolic BP 73.2 76.4 75.7 81.4∗
Total cholesterol (mg/dL) 227 232 229 243
LDL cholesterol (mg/dL) 139 141 140.5 143
HDL cholesterol (mg/dL) 45 44.5 44 46
Triglycerides (mg/dL) 173 176 175 189∗
Fasting blood glucose (mg/dL) 109 112 111 117
Creatinine (mg/dL) 1.01 1.0 0.98 1.1
ST elevation MI 273 (45.1%) 35 (53.8%) 29 (53%) 6 (54.5%)
Non-ST elevation MI 331 (54.9%) 30 (56.2%) 25 (47%) 5 (45.5%)
TSH levels (Mu/L) 2.97 6.8∗ 6.3 12.5∗
Inhospital deaths 15 (2.48%) 5 (7.7%)∗ 2 (3.7%) 3 (27.27%)∗
History of heart failure 24 (3.97%) 5 (7.7%)∗ 2 (3.7) 3 (27.27%)∗
coagulation disturbances, hormonal and metabolic changes,
and changes in measurable factors such as homocysteine
and C-reactive protein, which are known to increase risk for
atherosclerotic disease.
Several authors support the early treatment of SCH.
We conclude that further studies are required to clarify the
association between clinical and subclinical alterations in
thyroid function, particularly the eﬀect of various degrees of
SCH on lipoprotein oxidation, in the onset and progression
of atherosclerosis, and hence cardiovascular morbidity.
There have been suggestions that age and gender may
haveanimpactonIHDrisk inpeoplewithSCH.Inourstudy
population, patients with SCH were older than euthyroid
group. This might also have impact on mortality and risk
proﬁle of this patient group.
Currently, the indications for therapy of SCH in the
general population are unclear. However, there is some evi-
dence that adverse vascular risk factors may be ameliorated
by L-T4 treatment [25–29]. In contrast, the eﬀect of L-T4
therapy on symptoms and well-being in SCH remains ill
deﬁned [25–28]. If therapy of SCH is to be considered on
prognostic grounds, the ﬁnding that SCH is a more marked
vascular risk factor in younger patients may have substan-
tial implications. Several individual studies have demon-
strated that SCH in advanced age may not be associated with
an adverse prognosis [13, 30]. Thus, there may be an age or
risk threshold, which remains to be deﬁned, above which
SCH should no longer be considered for treatment on
prognostic grounds alone. Only well-powered prospective
randomized studies with age-stratiﬁed groups, and vascular
events as the primary endpoint rather than surrogate
markers, will give clear answers to this complex question.
Before recommending routine screening of the general
population,large-scalerandomizedtrialsareneededtoprove
that treatment will improve quality of life in otherwise
healthy patients who have the mildly elevated TSH level (5–
10mIU/L) typical of most SCH cases. But authors of this
paper believe that clinicians should have a low threshold for
obtaining a serum TSHlevelin patientswith high risk for MI
and atherosclerotic heart disease.
There is biological plausibility to the premise that sub-
clinical thyroid dysfunction may cause adverse cardiac con-
sequences. Thyroid hormone has both inotropic and chron-
otropic eﬀects, and it is clear from studies of individuals
w i t ho v e r tt h y r o i dd i s e a s et h a th y p e r t h y r o i d i s ml e a d st o
increased heart rate, increased cardiac output, and decreased
systemic vascular resistance, whereas hypothyroidism has the
opposite eﬀects. In the continuum of thyroid dysfunction,
therefore, it is reasonable to propose that a dose-response
eﬀect exists, with more subtle cardiac impairment being4 ISRN Endocrinology
present in less extreme degrees of thyroid dysfunction. The
key challenges are measuring these more subtle cardiac
eﬀects and, more importantly, determining their clinical
relevance. Addressing these issues requires larger numbers
of study participants and more precise measurement of the
cardiac phenotype than in overt thyroid disease. It also
requires careful consideration of the age and underlying
cardiac status of the population studied. Mild perturbations
in circulating thyroid hormone levels could either provide
a tipping point for older individuals with marginal cardiac
r e s e r v eo rh a v en e g l i g i b l ee ﬀects in the face of stronger,
competing risk factors for cardiac dysfunction.
Thyroid hormone has many eﬀects on cardiovascular
hemodynamics, such as heart rate, cardiac output, systemic
vascular resistance, and blood pressure. Hypothyroidism is
associated with decreased endothelium-dependent vasodi-
latation, and animal studies have proposed that the thyroid
status alters the capacity for both formation and response
to nitric oxide. Endothelial dysfunction in patients with
SCH may result from reduction in nitric oxide availability,
with resultant impairment of ﬂow-mediated vasodilatation
[15, 31].
Recentstudiessuggestthatthereisevidenceofinﬂamma-
tion and endothelial dysfunction in hypothyroidism. Soluble
CD40 ligand (sCD40L) is a protein expressed mainly by acti-
vated platelets which have been found to be associated with
cardiovascular events. In a recent study, it has been shown
thatpatientswithovertandsubclinicalhypothyroidismasso-
ciated with chronic autoimmune thyroiditis had decreased
serum levels of sCD40L [32].
Studies have shown slowed left ventricular relaxation
time, increased vascular tone at rest, and left ventricular sys-
tolic dysfunction with exercise and impaired endothelial
function [33]. Some studies have shown improvement of
cardiaccontractibilityandsystolictimeintervalwithlevothy-
roxine therapy [33]. No evidence exists to support an asso-
ciation between heart failure and a serum TSH level of less
than 10.0mIU/L. Again, most studies were not categorized
fordegreesofTSHelevation,anddataremain insuﬃcientfor
a TSH level less than 10mIU/L but strongly suggestive for a
TSH level greater than 10mIU/L.
A double-blind, placebo-controlled trial examining the
relation between thyroid function and another risk factor for
atherosclerotic disease—CRP—found signiﬁcantly higher
concentrationsin patientswith clinicalandsubclinicalhypo-
thyroidism, and CRP levels rose further with worsening thy-
roid failure [34].
There is conﬂicting evidence concerning the eﬀect of
hypothyroidism on coagulation. Both increased and de-
creased platelet aggregation have been reported, with the
degree of severity determining the impact on coagulation
parameters [35, 36]. In moderate hypothyroidism (TSH 10–
50mU/L),ﬁbrinolyticactivity isreduced,withlowd-dimers,
increased α2-antiplasmin activity, and higher levels of anti-
gensto tissue plasminogen activator (t-PA) and plasminogen
activator inhibitor-1 (PAI-1) [36]. In severe hypothyroidism
(TSH > 50mU/L), d-dimer levels are increased and a 2-
antiplasmin activity and t-PA and PAI-1 antigen levels are
reduced [36]. These ﬁndings suggest that there is greater risk
of thrombosis, and hence of myocardial infarction, in mod-
erate hypothyroidism, and greater risk of hemorrhage in
severe hypothyroidism.
In conclusion, 65 patients (10.76%) had TSH levels be-
tween 4.5 and 20 in our study, and it is a considerable
amount. Large-scale studies are needed to clarify the eﬀects
of SCH on myocardial infarction both on etiologic and
prognostic grounds.
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